Does TB-500 need protecting from light?

Less than most peptides. There is no methionine to oxidise and no aromatic residue to photodegrade. Dark storage remains sensible but the specific liability is absent.

Why might I recover less than expected?

Adsorption to glass and plastic. A small, highly charged peptide binds surfaces, and at low concentrations that loss is significant.

Does it need a reducing agent?

No. There is no cysteine in the sequence.

TB-500 Storage, Stability and Reconstitution

The short answer

TB-500 is supplied lyophilised and is most stable dry, cold and dark. Its composition rules out the common chemical degradation routes, no disulfides, no methionine oxidation, no deamidation hotspot,leaving hydrolysis and, more practically, physical adsorption to container surfaces.

Key facts

Supplied as: White lyophilised powder
Disulfide risk: None (no cysteine)
Oxidation risk: Low (no methionine)
Deamidation: No asparagine
Main chemical route: Hydrolysis
Main practical loss: Adsorption to surfaces
Freeze-thaw: Avoid by aliquoting

Why the usual advice mostly does not apply

Most peptide storage guidance is written around cysteine and methionine, disulfide scrambling and thioether oxidation. TB-500 has neither, and no asparagine either, so deamidation at the classic hotspot is also absent. As a chemical entity it is unusually forgiving, and the standard emphasis on protecting from oxidation is largely beside the point here.

What actually degrades it

Hydrolysis of the peptide backbone, which water enables and which is why the lyophilised form is the stable one. Freeze-drying removes the participant in that reaction, and cold storage slows what remains. Seven residues means few bonds to hydrolyse, so even this is slow relative to a larger peptide.

Research material referenced

TB-500 5mg, third-party HPLC tested

Buy TB-500 · £23.99

The loss mechanism that matters more

Adsorption. A small, strongly charged peptide binds to glass and plastic, and at low working concentrations the fraction lost to the vial and pipette tips can be a substantial share of the material. This is a physical loss with no chemical signature. The peptide that remains is intact, there is simply less of it than the calculation assumed. Low-binding consumables and minimising transfers are the practical responses.

Reconstitution

Introduce diluent gently down the vial wall rather than onto the powder, and swirl rather than shake. Foaming indicates an air-liquid interface has been created, and peptides unfold at that interface before aggregating. TB-500 dissolves readily given its charge and hydrophilicity, so vigorous agitation is never necessary.

After reconstitution

Aliquot into single-use volumes. Repeated freeze-thaw cycling concentrates solutes at the advancing ice boundary and creates fresh interfaces each cycle. Damage that the absence of oxidation-prone residues does nothing to prevent. Chemical robustness is not the same as physical robustness.

A note if the material is the full protein

If a vial actually contains full-length thymosin beta-4 rather than the heptapeptide, this guidance is incomplete: the 43-residue protein has a different composition, including methionine, and correspondingly different vulnerabilities. Establishing which compound is present is a prerequisite to handling it correctly.

Frequently asked questions

Does TB-500 need protecting from light?: Less than most peptides. There is no methionine to oxidise and no aromatic residue to photodegrade. Dark storage remains sensible but the specific liability is absent.
Why might I recover less than expected?: Adsorption to glass and plastic. A small, highly charged peptide binds surfaces, and at low concentrations that loss is significant.
Does it need a reducing agent?: No. There is no cysteine in the sequence.

Extended research context

The TB-500 (Thymosin β4 fragment) deep dive

Deep dive: TB-500 vs full-length Thymosin Beta-4

'TB-500' is a synthetic peptide corresponding to the active 17-amino-acid actin-binding region of the endogenous 43-residue Thymosin Beta-4 protein. The two are not identical. TB-500 lacks the flanking sequence that gives full-length TB-4 additional binding partners. In the research literature, papers use 'Thymosin β4' when they mean the full protein and 'TB-500' or 'AcSDKP fragment' when they mean the shorter synthetic peptide. Reading a CoA carefully to see which molecule is in the vial matters. Mass spec is the definitive check.

Actin-binding as the core mechanism

The N-terminal region of TB-4 (and TB-500 by inheritance) contains the canonical actin-binding motif. This motif sequesters G-actin monomers, modulating the G:F actin equilibrium in cell cultures. That mechanism is why almost every mechanistic paper on TB-500 traces back to cytoskeletal reorganisation, cell migration, and models of tissue repair.

Handling considerations unique to TB-500

TB-500 is a 17-residue peptide with modest amphipathicity; it reconstitutes cleanly in bacteriostatic water but is sensitive to repeated freeze/thaw. Aliquoting into single-use volumes on first reconstitution preserves potency across a batch. HPLC on the batch CoA should show a single dominant peak; a doublet suggests deamidation.

Research applications

▸In vitro actin-polymerisation assays (G:F actin ratio measurement)
▸Cell-migration and wound-scratch assays in fibroblast lines
▸Angiogenesis models: tube-formation and endothelial migration assays
▸Analytical method development for short peptides on RP-HPLC
▸Reference-material comparisons against endogenous Thymosin β4

Handling checklist

✓Store lyophilised vials at −20 °C long-term
✓Reconstitute with bacteriostatic water (0.9% benzyl alcohol)
✓Aliquot immediately to avoid freeze/thaw cycles
✓Refrigerate reconstituted aliquots at 2–8 °C; use within 28 days
✓Confirm mass (~4,963 Da for TB-500) via CoA before study use

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Assuming TB-500 = full Thymosin β4

Fix: TB-500 is the 17-residue actin-binding fragment; check the CoA sequence.

✗ Repeated freeze/thaw

Fix: Aliquot at first reconstitution; each cycle degrades yield.

✗ Using tap water

Fix: Use bacteriostatic or sterile water only.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More TB-500 (Thymosin β4 fragment) articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum